ClinicalTrials.gg
TerminatedNCT05744375TRANSCENDERUpdated Apr 2, 2026Results posted

Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab

A Phase 2 interventional study of Trastuzumab deruxtecan in Locally Advanced Breast Cancer and Metastatic Breast Cancer, sponsored by Spanish Breast Cancer Research Group. Terminated at 19 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-02.

Sponsored by Spanish Breast Cancer Research Group · Phase 2, Interventional, and Treatment

How we know · 5 judgments

Why this study was terminated
The study stopped due to insufficient accrual (only two patients were included), and the sponsor has decided on its premature termination.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
2
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 59 studies testing trastuzumab deruxtecan in Breast Neoplasms — 32 open to participants now, 46 under way, 8 of them phase 3. trastuzumab deruxtecan · Breast Neoplasms.

Enrollment
58th of 59
2 · median 138
Started
2023
with 5 others
Phase 2
34 of 59
24 open now
Registered
24th of 59
by date

Among the 59 studies testing trastuzumab deruxtecan in Breast Neoplasms, this one is the 58th largest by enrollment, is one of 6 that started in 2023, is one of 34 in phase 2, and was the 24th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

32 of the 59 studies testing trastuzumab deruxtecan in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

27 more — sign in →

By country, each count listing its studies:

All 32 open studies →

About trastuzumab deruxtecan

trastuzumab deruxtecan: first FDA approval 2019 (ENHERTU), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing trastuzumab deruxtecan in Breast Neoplasms, or all of them as a file.
02

Study summary

The goal of this national, multicenter single arm phase II clinical trial is to study the efficacy, safety and tolerability of the administration of Trastuzumab Deruxtecan (T-DXd) in HER2-positive locally advanced or metastatic breast cancer (MBC) patients resistant to trastuzumab plus pertuzumab plus taxane due to early relapse.

The main questions it aims to answer are:

  • To evaluate the antitumor activity of T-DXd in the first-line treatment of HER2-positive breast cancer patients resistant to trastuzumab-pertuzumab based therapy.
  • To assess other efficacy measures.
  • To evaluate safety and tolerability in all patients enrolled in the study.
  • To evaluate health-related quality of life (HRQoL). Forty-one evaluable patients will be treated with trastuzumab deruxtecan (T-DXd) 5.4 mg/kg IV every 3 weeks (± 3 days). Patients will receive T-DXd until unacceptable toxicity, progressive disease, informed consent withdrawal, or other discontinuation criterion is met.
Read the detailed description

This is a national, multicenter single arm phase II clinical trial to study the efficacy, safety and tolerability of the administration of Trastuzumab Deruxtecan (T-DXd) in HER2-positive locally advanced or MBC patients resistant to trastuzumab plus pertuzumab plus taxane due to early relapse.

Eligible patients will be enrolled and treated with T-DXd 5.4 mg/kg IV every 3 weeks.

The T-DXd dose will be recalculated in the event that patients experience body weight variations greater than 10% during the treatment period.

All patients enrolled will receive study therapy until radiographic or symptomatic progressive disease, unacceptable toxicity or withdraw of the informed consent, whatever occurs first.

Study population:

HER2-positive locally advanced or MBC patients who have not received prior chemotherapy or HER2 targeted therapy for advanced disease and with a Disease-Free Interval (DFI) of \<12 months from the end of prior (neo)adjuvant anti-HER2 therapy.

Study Duration: The start date of the study is the date of the first site activation. Recruitment period will occur during approximately 24 months from the first patient in.

The end date of the study is the date of the last visit of the last patient (LPLV), including follow-up. The duration of the study will be approximately 68 months from the first patient in.

Performing exploratory objectives will be independent of the date of the end of the study.

03

Conditions studied

  • Locally Advanced Breast Cancer
  • Metastatic Breast Cancer

Browse trials for

Keywords

  • Trastuzumab deruxtecan
  • HER2-positive
  • Advanced Breast Cancer
  • Metastatic Breast Cancer
  • resistant to prior (neo) adjuvant anti-HER2 therapy.
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written and signed obtained prior to any study-specific procedure.
  2. Male or female patients of at least 18 years of age.
  3. (ECOG) Performance Status ≤ 1.
  4. ≥ 12 weeks.
  5. Recurrent breast cancer that is unresectable locally advanced or .
  6. documented -positive status by local laboratory determination, preferably on the most recent available Formalin-fixed paraffin-embedded (FFPE) tumor sample, according to the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) international guidelines valid at the time of the assay. In case of discordance in HER2 status in different , the result from the most recent biopsy will be used.
  7. Pathologically documented Hormone Receptor (HR)-positive or -negative by local laboratory determination, preferably on the most recent available FFPE tumor sample, and according to ASCO/CAP international guidelines valid at the time of the assay. In case of discordance in HR status in different biopsies, the result from the most recent biopsy will be used.
  8. Prior anti-HER2 based therapy (with trastuzumab plus pertuzumab plus taxane with or without trastuzumab-emtansine) in the (neo) setting with a relapse while on therapy or within 12 months from the end of last anti-HER2 therapy.
  9. assessed by the investigator based on version 1.1.
  10. (LVEF) ≥ 50% measured by multiple-gated acquisition scan (MUGA) or echocardiogram (ECHO).
  11. Adequate organ and marrow function defined as follows:

    1. (ANC) ≥ 1,500/mm3 (1.5x109/L).
    2. count ≥ 100,000/mm3 (100x109/L).
    3. ≥ 9g/dL (90g/L).
    4. ≥ 30 mL/min as calculated using the standard method for the institution.
    5. Total serum ≤ 1.5 × (ULN) if no liver metastases or \< 3 × ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinemia) or liver metastases at baseline.
    6. (AST) and/or alanine aminotransferase (ALT) ≤ 3.0 x ULN (\< 5.0 × ULN in participants with liver metastases).
    7. Alkaline phosphatase (ALP) ≤ 2.5 x ULN (≤ 5.0 x ULN if bone or liver metastases are present).
    8. Serum albumin ≥ 2.5 g/dL
  12. (INR) and activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN.
  13. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.
  14. Negative serum pregnancy test with a sensitivity of at least 25 milliInternational Units per milliliter of urine (mIU/mL) (unless permanent previous sterilization procedure such as bilateral salpingectomy, bilateral oophorectomy, or complete hysterectomy) for premenopausal women, and for women who have experienced menopause onset \< 12 months prior to first dose of therapy.

Exclusion criteria

Exclusion Criteria:

  1. Prior chemotherapy or -targeted therapy for locally advanced or MBC (one prior endocrine therapy regimen for MBC without concurrent anti-HER2 therapy or radiotherapy is allowed).
  2. Ineligible for treatment with T-DXd.
  3. Any substance abuse or other medical conditions that, in the investigator's opinion, may interfere with patient's participation or study results.
  4. Patients with spinal cord compression, or clinically active central nervous system (CNS) . Participants with clinically inactive or treated brain metastases that are no longer symptomatic, and no needing or anticonvulsants may be enrolled in the study.
  5. Active or prior documented interstitial lung disease (ILD)/pneumonitis or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.
  6. Lung criteria:

    1. Lung-specific intercurrent illnesses including, but not limited to, any underlying pulmonary disorder (e.g. pulmonary emboli within three months of the study enrollment, severe asthma, severe (COPD), restrictive lung disease, pleural effusion etc.).
    2. Any , connective tissue or inflammatory disorders (e.g. Rheumatoid arthritis, Sjogren's, sarcoidosis etc.) where there is documented, or a suspicion of pulmonary involvement at the time of screening. Full details of the disorder should be recorded in the electronic Case Report Form (eCRF) for patients who are enrolled in the study.
    3. Prior pneumonectomy.
  7. Medical history of myocardial infarction within 6 months before registration, symptomatic congestive heart failure (CHF), troponin levels consistent with myocardial infarction as defined according to American College of Cardiologists (ACC) guidelines, unstable angina, or serious cardiac arrhythmia requiring treatment. corrected using Fridericia's formula (QTcF) > 470 msec (females) or > 450 msec (males) based on average of the screening triplicate 12-lead .
  8. History of active primary immunodeficiency, known (HIV), active Virus (HBV) or Virus (HCV).
  9. Patients who received before treatment starts:

    1. Any agent within 4 weeks.
    2. Chemotherapy within a period of time that is shorter than the cycle duration used for that treatment (e.g. \< 3 weeks for fluorouracil, doxorubicine, epirubicin or \< 1 week for weekly chemotherapy).
    3. Targeted therapy (e.g., antibodies): up to 4 weeks prior to starting study treatment.
    4. Endocrine therapy: tamoxifen or aromatase inhibitor within 2 weeks prior to starting study treatment.
    5. Radiotherapy within 2 weeks prior to starting study treatment. Patients who received prior radiotherapy to >25% of bone marrow are not eligible regardless of when it was administered.
    6. Major surgery or other anti-cancer therapy not previously specified within 4 weeks prior to starting study treatment.

    In any case, resolution of all acute toxic effects of prior anti-cancer therapy or surgical procedures to version 5.0 grade ≤ 1 (except alopecia or other toxicities not considered a safety risk for the patient at investigator´s discretion) is mandatory.Patients may be enrolled with chronic, stable grade 2 toxicities (defined as no worsening to > grade 2 for at least 3 months prior to enrollment and managed with standard of care treatment) that the investigator deems related to previous anticancer therapy, such as: chemotherapy-induced neuropathy or fatigue and immunotherapy-induced toxicities (e.g. endocrinopathies as hypothyroidism/hyperthyroidism, type 1 diabetes, hypoglycemia, adrenal insufficiency, adrenalitis and skin hypopigmentation [vitiligo]).

  10. Have a diagnosis of any other within 3 years prior to inclusion, except for adequately resected non-melanoma skin cancer, curatively treated in-situ disease, other solid tumors curatively treated and contralateral breast cancer.
  11. Receipt of live, attenuated vaccine within 30 days prior to the first dose of T-DXd.
  12. Prior treatment with T-DXd or allergic reaction to trastuzumab.
  13. Patient is pregnant or breastfeeding or planning to become pregnant within the projected duration of the trial, starting at screening and through 7 months after the last dose of the study treatment. Male patients whose partners plan to become pregnant within the duration of the trial, starting at screening and through 4 months after the last dose of the study treatment.

    ✓ For premenopausal women it is necessary an agreement to remain complete abstinent or use single or combined non-hormonal methods that result in a failure rate of \< 1% per year during the treatment period and for at least 7 months after the last dose of study treatment.

    • Examples of non-hormonal contraceptive methods with a failure rate of \< 1% per year include bilateral tubal litigation, male sterilization, and certain intrauterine devices (provided coils are copper banded).
    • Alternative, two methods (e.g. two barrier methods such as a condom and a cervical cap or combined with estrogen and progestogen) may be combined to achieve a failure rate of \< 1% per year. Barrier methods must always be supplemented with the use of a spermicide.

    Female patients must not donate, or retrieve for their own use, ova from the time of enrollment and throughout the study treatment period, and for at least 7 months after the final study drug administration. They should refrain from breastfeeding throughout this time. Preservation of ova may be considered prior to enrollment in this study.

    ✓ For men it is necessary an agreement to remain complete abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and to refrain from donating sperm during the same period, as defined below with female partners of or pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 4 months after the last dose of study treatment to avoid exposing the embryo.

    Abstinence is only acceptable if it is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.

  14. Uncontrolled intercurrent illness including uncontrolled infection requiring intravenous (IV) antibiotics, antivirals, or antifungals.
  15. Has substance abuse or any other medical/psychological conditions that may, in the opinion of the investigator, interfere with the patient's participation in the clinical study or evaluation of the clinical study results.
Terms in these criteria, in plain language(35)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    Trastuzumab deruxtecan (T-DXd)

    All patients enrolled will be treated with trastuzumab deruxtecan (T-DXd) 5.4 mg/kg IV every 3 weeks (± 3 days). The subject's weight at baseline will be used to calculate the initial dose. If during the course of treatment the subject's weight changes by ± 10% of the baseline weight, the subject's dose will be recalculated based on the subject's updated weight. Patients will receive T-DXd until unacceptable toxicity, progressive disease (PD), informed consent withdrawal, or other discontinuation criterion is met.

    Drug: Trastuzumab deruxtecan

Interventions

  • All patients enrolled will be treated with trastuzumab deruxtecan (T-DXd) 5.4 mg/kg IV every 3 weeks (± 3 days). The subject's weight at baseline will be used to calculate the initial dose. If during the course of treatment the subject's weight changes by ± 10% of the baseline weight, the subject's dose will be recalculated based on the subject's updated weight. Patients will receive T-DXd until unacceptable toxicity, progressive disease (PD), informed consent withdrawal, or other discontinuation criterion is met.

    Also known as: Enhertu

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    Objective Response Rate (ORR) is defined as the rate of complete response (CR) plus partial response (PR) based on the investigator's assessment using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1., out of the patients who received at least 1 dose of treatment (efficacy population). Per RECIST, CR is defined as the disappearance of all target lesions; PR is defined as an \>=30% decrease in the sum of the longest diameter of target lesions. The ORR will be reported, including a 95% Confidence Interval (CI) using the Clopper-Pearson method. A sensitivity analysis will be performed using the Intent to treat population (ITT) population.

    Time frame: Through study treatment, and average of 18 months

Secondary outcomes

  1. Progression-Free Survival (PFS)

    Progression-Free Survival (PFS) is defined as the time from the date of enrollment to the date of disease progression, based on the investigator's assessment using RECIST version 1.1., or death from any cause, whichever occurs first. PFS data will be censored on the date of the last tumor assessment on study for patients who do not have objective tumor progression and who have not died due to any cause while on study. Additionally, patients who start a new anti-cancer therapy prior to documented progression disease (PD) will be censored at the date of the last tumor assessment prior to the start of the new therapy. PD is defined using RECIST, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. PFS analysis will be performed in the safety population. PFS will be assessed using the Kaplan-Meier method. The median event time and 95% CI will be estimated if reached.

    Time frame: Through study treatment, and average of 18 months

  2. Overall Survival (OS)

    Overall Survival (OS) is defined as the time from the date of enrollment to the date of death from any cause. OS data will be censored on the last date the patient is known to be alive. OS analysis will be performed in the safety population. OS will be assessed using the Kaplan-Meier method. The median event time and 95% CI will be estimated if reached.

    Time frame: Through study, and average of 36 months

  3. Time to Treatment Response (TTR)

    Time to treatment response (TTR) is defined as the time from the date of enrollment to the date of first documentation of objective tumor response (CR or PR). TTR analysis will be performed in the efficacy population in patients with an Objective Response (OR). TTR will be assessed using the Kaplan-Meier method. The median event time and 95% CI will be estimated.

    Time frame: Through study treatment, and average of 18 months

  4. Duration of Response (DoR)

    Duration of response (DoR) is defined as the time from the date of first documentation of objective tumor response (CR or PR) to the date of first documented progressive disease based on the investigator's assessment using RECIST version 1.1., or death from any cause, whichever occurs first. DoR will be censored on the date of the last tumor assessment on study for patients who do not have objective tumor progression and who have not died due to any cause while on study. Additionally, patients who start a new anti-cancer therapy prior to documented PD will be censored at the date of the last tumor assessment prior to the start of the new therapy. DoR analysis will be performed in the efficacy population in patients with an OR. DoR will be estimated using Kaplan-Meier methods. The median event time and 95% CI will be estimated if reached.

    Time frame: Through study treatment, and average of 18 months

  5. The Number of Participants Who Experienced Adverse Events (AE) Related to Study Treatment

    Safety assessments will be performed at baseline and during the study: Vital signs assessments (blood pressure, pulse and body temperature), measurement of left ventricular ejection fraction, triplicate 12-lead electrocardiogram, laboratory assessments (hemoglobin, White Blood Cell, Absolute Neutrophil Count, Lymphocytes, platelet count, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, total bilirubin, serum creatinine, creatinine clearance, sodium, potassium, total calcium, blood urea nitrogen (or urea), albumin, Troponin Test, Coagulation testing (International Normalized Ratio, activated partial thromboplastin time), pregnancy test , ophthalmologic assessments (visual acuity testing, slit lamp examination, fundoscopy), Viral serology. AEs will be graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. The toxicity of study treatments will be evaluated in the safety population.

    Time frame: Through study treatment, and average of 18 months

  6. Changes From Baseline in the Global Health Status Score (GHS)

    Change from baseline in the GHS and each scale of the EORTC Quality of Life Questionnaire-Core 30 (QLQ-C30) will be presented at each scheduled time point for the GHS score and each of the functionals and symptoms scales from the QLQ-C30 questionnaires. Longitudinal analysis of scores will be performed using linear mixed models. QLQ-C30 is composed of both multi-item scales and single-item measures. These include 5 functional scales, 3 symptom scales, a global health status/QoL scale, and 6 single items. Each of the multi-item scales includes a different set of items - no item occurs in more than one scale. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/QoL represents a high QoL, but a high score for a symptom scale/item represents a high level of symptomatology/problems.

    Time frame: Through study treatment, and average of 18 months

  7. Time to Deterioration (TTD) in Quality of Life (QoL)

    Time to deterioration (TTD) in QoL is defined as the time from the date of enrollment to the date of first detection of a deterioration event. A deterioration event is defined as an increase of ≥ minimally important difference (MID) from baseline for the EORTC QLQ-C30 symptom scales and a decrease of ≥ MID from baseline for the EORTC QLQ-C30 functional scales and GHS scale. It will be assessed using the Kaplan-Meier. Method. The median event time and 95% CI for the median will be estimated if reached. TTD will be censored at the date of the last QoL assessment prior to the start of a new therapy.

    Time frame: Through study treatment, and average of 18 months

Other outcomes

  1. Progression-Free Survival 2 (PFS2)

    PFS2 is defined as the time from the date of enrollment to the date of disease progression to the second line of therapy. PFS2 data will be censored on the last date in which the patient was known not to have tumor progression or death due to any cause within the second line of therapy. Additionally, patients who start a third line therapy prior to progression to the second line will be censored at the date of the start of the third line therapy. PFS2 will be performed in the safety population. PFS2 will be assessed using the Kaplan-Meier method. The median event time and 95% CI will be estimated if reached.

    Time frame: Through study, and average of 36 months

  2. Progression-Free Survival 3 (PFS3)

    PFS3 is defined as the time from the date of enrollment to the date of disease progression to the third line of therapy. PFS2 data will be censored on the last date in which the patient was known not to have tumor progression or death due to any cause within the second line of therapy. Additionally, patients who start a third line therapy prior to progression to the second line will be censored at the date of the start of the third line therapy. PFS3 will be performed in the safety population. PFS3 will be assessed using the Kaplan-Meier method. The median event time and 95% CI will be estimated if reached.

    Time frame: Through study, and average of 36 months

07

Results

Posted Mar 12, 2026
Limitations and caveats
Recruitment for the study was closed on January 17, 2025, due to insufficient accrual (only two patients were included), and the sponsor decided on its premature termination.

Participant flow

Participant flow — Overall Study
MilestoneTrastuzumab Deruxtecan (T-DXd)
Started2
Completed1
Not completed1
Withdrew: Study terminated by sponsor1

Outcome measures

PrimaryObjective Response Rate (ORR)

Objective Response Rate (ORR) is defined as the rate of complete response (CR) plus partial response (PR) based on the investigator's assessment using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1., out of the patients who received at least 1 dose of treatment (efficacy population). Per RECIST, CR is defined as the disappearance of all target lesions; PR is defined as an \>=30% decrease in the sum of the longest diameter of target lesions. The ORR will be reported, including a 95% Confidence Interval (CI) using the Clopper-Pearson method. A sensitivity analysis will be performed using the Intent to treat population (ITT) population.

Time frame:
Through study treatment, and average of 18 months
Reported as:
Number · participants
Objective Response Rate (ORR)
participantsTrastuzumab Deruxtecan (T-DXd)
Objective Response Rate (ORR)1
SecondaryProgression-Free Survival (PFS)

Progression-Free Survival (PFS) is defined as the time from the date of enrollment to the date of disease progression, based on the investigator's assessment using RECIST version 1.1., or death from any cause, whichever occurs first. PFS data will be censored on the date of the last tumor assessment on study for patients who do not have objective tumor progression and who have not died due to any cause while on study. Additionally, patients who start a new anti-cancer therapy prior to documented progression disease (PD) will be censored at the date of the last tumor assessment prior to the start of the new therapy. PD is defined using RECIST, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. PFS analysis will be performed in the safety population. PFS will be assessed using the Kaplan-Meier method. The median event time and 95% CI will be estimated if reached.

Time frame:
Through study treatment, and average of 18 months
Reported as:
Median · month
Progression-Free Survival (PFS)
monthTrastuzumab Deruxtecan (T-DXd)
Progression-Free Survival (PFS)NA (5.9 to NA)
SecondaryOverall Survival (OS)

Overall Survival (OS) is defined as the time from the date of enrollment to the date of death from any cause. OS data will be censored on the last date the patient is known to be alive. OS analysis will be performed in the safety population. OS will be assessed using the Kaplan-Meier method. The median event time and 95% CI will be estimated if reached.

Time frame:
Through study, and average of 36 months
Reported as:
Median · month
Overall Survival (OS)
monthTrastuzumab Deruxtecan (T-DXd)
Overall Survival (OS)NA (NA to NA)
SecondaryTime to Treatment Response (TTR)

Time to treatment response (TTR) is defined as the time from the date of enrollment to the date of first documentation of objective tumor response (CR or PR). TTR analysis will be performed in the efficacy population in patients with an Objective Response (OR). TTR will be assessed using the Kaplan-Meier method. The median event time and 95% CI will be estimated.

Time frame:
Through study treatment, and average of 18 months
Reported as:
Mean · month
Time to Treatment Response (TTR)
monthTrastuzumab Deruxtecan (T-DXd)
Time to Treatment Response (TTR)1.9 (NA to NA)
SecondaryDuration of Response (DoR)

Duration of response (DoR) is defined as the time from the date of first documentation of objective tumor response (CR or PR) to the date of first documented progressive disease based on the investigator's assessment using RECIST version 1.1., or death from any cause, whichever occurs first. DoR will be censored on the date of the last tumor assessment on study for patients who do not have objective tumor progression and who have not died due to any cause while on study. Additionally, patients who start a new anti-cancer therapy prior to documented PD will be censored at the date of the last tumor assessment prior to the start of the new therapy. DoR analysis will be performed in the efficacy population in patients with an OR. DoR will be estimated using Kaplan-Meier methods. The median event time and 95% CI will be estimated if reached.

Time frame:
Through study treatment, and average of 18 months
Reported as:
Median · month
Duration of Response (DoR)
monthTrastuzumab Deruxtecan (T-DXd)
Duration of Response (DoR)NA (NA to NA)
SecondaryThe Number of Participants Who Experienced Adverse Events (AE) Related to Study Treatment

Safety assessments will be performed at baseline and during the study: Vital signs assessments (blood pressure, pulse and body temperature), measurement of left ventricular ejection fraction, triplicate 12-lead electrocardiogram, laboratory assessments (hemoglobin, White Blood Cell, Absolute Neutrophil Count, Lymphocytes, platelet count, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, total bilirubin, serum creatinine, creatinine clearance, sodium, potassium, total calcium, blood urea nitrogen (or urea), albumin, Troponin Test, Coagulation testing (International Normalized Ratio, activated partial thromboplastin time), pregnancy test , ophthalmologic assessments (visual acuity testing, slit lamp examination, fundoscopy), Viral serology. AEs will be graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. The toxicity of study treatments will be evaluated in the safety population.

Time frame:
Through study treatment, and average of 18 months
Reported as:
Count of participants · Participants
The Number of Participants Who Experienced Adverse Events (AE) Related to Study Treatment
ParticipantsTrastuzumab Deruxtecan (T-DXd)
The Number of Participants Who Experienced Adverse Events (AE) Related to Study Treatment2
SecondaryChanges From Baseline in the Global Health Status Score (GHS)

Change from baseline in the GHS and each scale of the EORTC Quality of Life Questionnaire-Core 30 (QLQ-C30) will be presented at each scheduled time point for the GHS score and each of the functionals and symptoms scales from the QLQ-C30 questionnaires. Longitudinal analysis of scores will be performed using linear mixed models. QLQ-C30 is composed of both multi-item scales and single-item measures. These include 5 functional scales, 3 symptom scales, a global health status/QoL scale, and 6 single items. Each of the multi-item scales includes a different set of items - no item occurs in more than one scale. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/QoL represents a high QoL, but a high score for a symptom scale/item represents a high level of symptomatology/problems.

Time frame:
Through study treatment, and average of 18 months
Reported as:
Mean · units on a scale
Changes From Baseline in the Global Health Status Score (GHS)
units on a scaleTrastuzumab Deruxtecan (T-DXd)
Basal58.33 (-365 to 481.9)
End of Treatment62.5 (-308 to 433.1)
SecondaryTime to Deterioration (TTD) in Quality of Life (QoL)

Time to deterioration (TTD) in QoL is defined as the time from the date of enrollment to the date of first detection of a deterioration event. A deterioration event is defined as an increase of ≥ minimally important difference (MID) from baseline for the EORTC QLQ-C30 symptom scales and a decrease of ≥ MID from baseline for the EORTC QLQ-C30 functional scales and GHS scale. It will be assessed using the Kaplan-Meier. Method. The median event time and 95% CI for the median will be estimated if reached. TTD will be censored at the date of the last QoL assessment prior to the start of a new therapy.

Time frame:
Through study treatment, and average of 18 months
Reported as:
Median · month
Time to Deterioration (TTD) in Quality of Life (QoL)
monthTrastuzumab Deruxtecan (T-DXd)
Time to Deterioration (TTD) in Quality of Life (QoL)NA (NA to NA)
Other pre-specifiedProgression-Free Survival 2 (PFS2)

PFS2 is defined as the time from the date of enrollment to the date of disease progression to the second line of therapy. PFS2 data will be censored on the last date in which the patient was known not to have tumor progression or death due to any cause within the second line of therapy. Additionally, patients who start a third line therapy prior to progression to the second line will be censored at the date of the start of the third line therapy. PFS2 will be performed in the safety population. PFS2 will be assessed using the Kaplan-Meier method. The median event time and 95% CI will be estimated if reached.

Time frame:
Through study, and average of 36 months
Reported as:
Median · month
Progression-Free Survival 2 (PFS2)
monthTrastuzumab Deruxtecan (T-DXd)
Progression-Free Survival 2 (PFS2)NA (NA to NA)
Other pre-specifiedProgression-Free Survival 3 (PFS3)

PFS3 is defined as the time from the date of enrollment to the date of disease progression to the third line of therapy. PFS2 data will be censored on the last date in which the patient was known not to have tumor progression or death due to any cause within the second line of therapy. Additionally, patients who start a third line therapy prior to progression to the second line will be censored at the date of the start of the third line therapy. PFS3 will be performed in the safety population. PFS3 will be assessed using the Kaplan-Meier method. The median event time and 95% CI will be estimated if reached.

Time frame:
Through study, and average of 36 months
Reported as:
Median · month
Progression-Free Survival 3 (PFS3)
monthTrastuzumab Deruxtecan (T-DXd)
Progression-Free Survival 3 (PFS3)NA (NA to NA)

Adverse events

Collected over AEs have been recorded through study completion, an average of 1 year.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trastuzumab Deruxtecan (T-DXd)0/2 (0%)1/2 (50%)2/2 (100%)
Most frequent serious events
Most frequent serious events
EventTrastuzumab Deruxtecan (T-DXd)
PneumonitisRespiratory, thoracic and mediastinal disorders1/2
Most frequent other events
Most frequent other events
EventTrastuzumab Deruxtecan (T-DXd)
NauseasGastrointestinal disorders2/2
AstheniaGeneral disorders1/2
DiarrheaGastrointestinal disorders1/2
Dry eyeEye disorders1/2
Left humerus fractureInjury, poisoning and procedural complications1/2
Ocular toxicityEye disorders1/2
PneumonitisRespiratory, thoracic and mediastinal disorders1/2
VomitingGastrointestinal disorders1/2

Baseline characteristics

Only 2 patients were included in the study, so it was not possible to analyze data.

Age, Categorical
Age, Categorical(Participants)Trastuzumab Deruxtecan (T-DXd)
<=18 years0
Between 18 and 65 years2
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)Trastuzumab Deruxtecan (T-DXd)
Female2
Male0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Trastuzumab Deruxtecan (T-DXd)
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White2
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Trastuzumab Deruxtecan (T-DXd)
Spain2
08

Study locations

19 sites
  • Hospital Universitario de Jeréz De La Frontera
    Cadiz, Andalusia 11407, Spain
  • Hospital Universitario de Jaén
    Jaén, Andalusia 23007, Spain
  • Hospital Universitario Marqués de Valdecilla
    Santander, Cantabria 39008, Spain
  • Hospital Universitario de Fuenlabrada
    Fuenlabrada, Madrid 28942, Spain
  • Hospital Universitario Puerta de Hierro de Majadahonda
    Majadahonda, Madrid 28222, Spain
  • Hospital Universitario Son Espases
    Palma de Mallorca, Mallorca 07120, Spain
  • Hospital Galdakao-Usansolo
    Galdakao, Vizcaya 48960, Spain
  • Complejo Hospitalario Universitario A Coruña (CHUAC)
    A Coruña, 15006, Spain
  • Hospital San Juan de Alicante
    Alicante, 03550, Spain
  • Hospital Universitario de Badajoz
    Badajoz, 06080, Spain
  • Hospital del Mar
    Barcelona, 08003, Spain
  • Hospital Universitario San Pedro de Alcántara
    Cáceres, 10003, Spain
  • Hospital Universitario Clínico San Cecilio
    Granada, 18016, Spain
  • Hospital Universitario Arnau de Vilanova de Lleida
    Lleida, 25198, Spain
  • Hospital General Universitario Gregorio Marañón
    Madrid, 28007, Spain
  • Hospital Universitario Ramón y Cajal
    Madrid, 28034, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Hospital Universitario Virgen del Rocío
    Seville, 41013, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2023 to primary completion in Jul 2025, 21 months.

Results were first posted in Mar 2026, 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2023
First posted
Feb 27, 2023
StartActual
Sep 28, 2023
Primary completionActual
Jul 17, 2025
CompletionActual
Jul 17, 2025
Results first posted
Mar 12, 2026
Last update
Apr 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05744375
Lead sponsor
Spanish Breast Cancer Research Group
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
Feb 27, 2023
Start date
Sep 28, 2023
Primary completion
Jul 17, 2025
Completion
Jul 17, 2025
Results posted
Mar 12, 2026
Last update
Apr 2, 2026

Study contacts

Study Director Study Director
study director · Hospital General Universitario Gregorio Marañón. Madrid, Spain.
Study Director Study Director
study director · Hospital del Mar. Barcelona, Spain.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab deruxtecan

Start the discussion